Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Cathy Eng

Showing results (241-250 of 315) with videos related to

Pageof 32
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 2, 2006
Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastasesJean-Nicolas Vauthey, Timothy M Pawlik, Dario Ribero, et al.
JCO Precision Oncology|September 14, 2020
Identification of Actionable Genomic Alterations Using Circulating Cell-Free DNANora S Sánchez, Michael P Kahle, Ann Marie Bailey, et al.
International Journal of Radiation Oncology, Biology, Physics|January 22, 2008
Patterns of locoregional recurrence after surgery and radiotherapy or chemoradiation for rectal cancerTse-Kuan Yu, Priya R Bhosale, Christopher H Crane, et al.
Nature Reviews. Cancer|February 20, 2025
Defining a 'cells to society' research framework for appendiceal tumoursAndreana N Holowatyj, Michael J Overman, Konstantinos I Votanopoulos, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 17, 2009
Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistanceScott Kopetz, Paulo M Hoff, Jeffrey S Morris, et al.
American Journal of Clinical Oncology|June 7, 2006
Clinical and pathologic predictors of locoregional recurrence, distant metastasis, and overall survival in patients treated with chemoradiation and mesorectal excision for rectal cancerPrajnan Das, John M Skibber, Miguel A Rodriguez-Bigas, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 13, 2018
Evaluation of Prexasertib, a Checkpoint Kinase 1 Inhibitor, in a Phase Ib Study of Patients with Squamous Cell CarcinomaDavid S Hong, Kathleen Moore, Manish Patel, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 20, 2019
Cell-free Circulating Tumor DNA Variant Allele Frequency Associates with Survival in Metastatic CancerSeyed Pairawan, Kenneth R Hess, Filip Janku, et al.
The Oncologist|April 4, 2020
A Practical Approach to the Management of Cancer Patients During the Novel Coronavirus Disease 2019 (COVID-19) Pandemic: An International Collaborative GroupHumaid O Al-Shamsi, Waleed Alhazzani, Ahmad Alhuraiji, et al.
Nature Communications|May 9, 2025
Ligand-activated EGFR/MAPK signaling but not PI3K, are key resistance mechanisms to EGFR-therapy in colorectal cancerXueping Qu, Habib Hamidi, Radia M Johnson, et al.
Pageof 32

Showing results (241-250 of 315) with videos related to

Sort By:
Pageof 32
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 2, 2006
Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastasesJean-Nicolas Vauthey, Timothy M Pawlik, Dario Ribero, et al.
JCO Precision Oncology|September 14, 2020
Identification of Actionable Genomic Alterations Using Circulating Cell-Free DNANora S Sánchez, Michael P Kahle, Ann Marie Bailey, et al.
International Journal of Radiation Oncology, Biology, Physics|January 22, 2008
Patterns of locoregional recurrence after surgery and radiotherapy or chemoradiation for rectal cancerTse-Kuan Yu, Priya R Bhosale, Christopher H Crane, et al.
Nature Reviews. Cancer|February 20, 2025
Defining a 'cells to society' research framework for appendiceal tumoursAndreana N Holowatyj, Michael J Overman, Konstantinos I Votanopoulos, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 17, 2009
Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistanceScott Kopetz, Paulo M Hoff, Jeffrey S Morris, et al.
American Journal of Clinical Oncology|June 7, 2006
Clinical and pathologic predictors of locoregional recurrence, distant metastasis, and overall survival in patients treated with chemoradiation and mesorectal excision for rectal cancerPrajnan Das, John M Skibber, Miguel A Rodriguez-Bigas, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 13, 2018
Evaluation of Prexasertib, a Checkpoint Kinase 1 Inhibitor, in a Phase Ib Study of Patients with Squamous Cell CarcinomaDavid S Hong, Kathleen Moore, Manish Patel, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 20, 2019
Cell-free Circulating Tumor DNA Variant Allele Frequency Associates with Survival in Metastatic CancerSeyed Pairawan, Kenneth R Hess, Filip Janku, et al.
The Oncologist|April 4, 2020
A Practical Approach to the Management of Cancer Patients During the Novel Coronavirus Disease 2019 (COVID-19) Pandemic: An International Collaborative GroupHumaid O Al-Shamsi, Waleed Alhazzani, Ahmad Alhuraiji, et al.
Nature Communications|May 9, 2025
Ligand-activated EGFR/MAPK signaling but not PI3K, are key resistance mechanisms to EGFR-therapy in colorectal cancerXueping Qu, Habib Hamidi, Radia M Johnson, et al.
Pageof 32